Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$558.87 USD
+13.41 (2.46%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $559.71 +0.84 (0.15%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth D Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
REGN 558.87 +13.41(2.46%)
Will REGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nonfarm Payrolls Come in SIgnificantly Below Expectations
Jobs Shrink in the Summer of '25, Pre-Markets Lower
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for REGN
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
Regeneron (REGN) Reports Strong Q2 2025 Driven by Key Products
Regeneron outlines path to $17B Dupixent annual sales and initiates 10 Lynozyfic registrational trials amid robust Q2 growth
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
Regeneron (REGN) Price Target Cut Amid Eylea Performance Concerns